A PHASE 2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162b2 RNA-BASED VACCINE CANDIDATES FOR SARS-CoV-2 NEW VARIANTS IN HEALTHY INDIVIDUALS
Latest Information Update: 31 Mar 2025
At a glance
- Drugs Tozinameran (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions; Pharmacodynamics
- Sponsors BioNTech
Most Recent Events
- 28 Mar 2025 Status changed from active, no longer recruiting to completed.
- 19 Sep 2024 Planned End Date changed from 30 Dec 2024 to 19 Mar 2025.
- 19 Sep 2024 Planned primary completion date changed from 30 Dec 2024 to 19 Mar 2025.